-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RfD5vpAH2VVBDkzm0rbLHrobKwgT1sa9ue3UzyaSDPfv7rxbV9Ri6xfuhFvrYz2e mPAiw7Y35tVRGrWx3u/OEA== 0001144204-06-029436.txt : 20060724 0001144204-06-029436.hdr.sgml : 20060724 20060724143613 ACCESSION NUMBER: 0001144204-06-029436 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20060724 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060724 DATE AS OF CHANGE: 20060724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FAMILYMEDS GROUP, INC. CENTRAL INDEX KEY: 0000921878 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 341755390 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15445 FILM NUMBER: 06976297 BUSINESS ADDRESS: STREET 1: 312 FARMINGTON AVENUE CITY: FARMINGTON STATE: CT ZIP: 06032-1968 BUSINESS PHONE: 8606761222 MAIL ADDRESS: STREET 1: 312 FARMINGTON AVENUE CITY: FARMINGTON STATE: CT ZIP: 06032-1968 FORMER COMPANY: FORMER CONFORMED NAME: DRUGMAX INC DATE OF NAME CHANGE: 20011128 FORMER COMPANY: FORMER CONFORMED NAME: DRUGMAX COM INC DATE OF NAME CHANGE: 20000208 FORMER COMPANY: FORMER CONFORMED NAME: NUTRICEUTICALS COM CORP DATE OF NAME CHANGE: 19990629 8-K 1 v048091_8k.htm Unassociated Document
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 24, 2006

Familymeds Group, Inc.
(Exact name of registrant as specified in its charter)

STATE OF NEVADA
           
1-15445
             
34-1755390
 
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 

312 Farmington Avenue
Farmington, CT 06032-1968
(Address of principal executive offices)

Registrant’s telephone number, including area code: (860) 676-1222


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 Item 8.01  Other Events.
 
On July 24, 2006, Familymeds Group, Inc. issued a press release announcing that it had recently implemented expense control initiatives which include a workforce reduction of over 20 employees at the Company headquarters in Farmington, Connecticut. A copy of this press release is furnished as Exhibit 99.1 to this report.

Item 9.01  Financial Statements and Exhibits.

99.1   Press Release dated July 24, 2006

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

     
  FAMILYMEDS GROUP, INC.
 
 
 
 
 
 
Dated: July 24, 2006 By:   /s/ Edgardo A. Mercadante 
 

Edgardo A. Mercadante, Chief Executive Officer,
President and Chairman of the Board
   



3

 
EXHIBIT INDEX


Exhibit
Number  Exhibit Description

99.1   Press Release dated July 24, 2006
 
4

 
EX-99.1 2 v048091_ex99-1.htm Unassociated Document
 
Exhibit 99.1
 
FOR IMMEDIATE RELEASE:
 
Familymeds Reports Significant Annualized Savings from Expense Control Initiatives,
Announces Workforce Reduction at Company Headquarters


Farmington, CT, July 24, 2006 - Familymeds Group, Inc. (Nasdaq: FMRX), a pharmacy and medical specialty product provider, today announced significant annualized savings from recently implemented expense control initiatives which include a workforce reduction of over 20 employees at the Company headquarters in Farmington, Connecticut. The associated personnel reduction in headquarters expenses coupled with general and administrative expense reductions is expected to result in an estimated decrease in total operating costs of approximately 20%, or $1.5 million for the second half of fiscal 2006. In addition, the Company expects to reduce pharmacy level operations expense by approximately 7% or $1.3 million in the second half of fiscal 2006, which the Company expects will not have any significant impact on the Company’s sales structure or customer operations.

Summarizing its annualized operating cost reductions for the next 12 months, the Company reported that headquarters expenses are expected to decrease approximately $2.9 million and pharmacy operations expenses are expected to decrease approximately $2.6 million. When annualized, total operating expense reductions will be approximately $5.5 million or 10% of overall estimated operating expenses. The Company expects to record a one time charge for severance and related expenses of approximately $150,000 in the third quarter of 2006.

Familymeds continues to employ more than 60 personnel in finance, operations, information technology and administrative functions at Company headquarters. In total, the Company employs approximately 840 individuals nationwide of which over 450 are full-time equivalents. Approximately 24% of Familymeds’ employees are pharmacists.

Ed Mercadante, R.Ph., Chairman, President and Chief Executive Officer of Familymeds, stated, “In the first half of 2006, we have successfully executed on customer relations, sales momentum and top line growth, and our strong unaudited preliminary sales increase of approximately 11% for second quarter 2006 compared to the second quarter 2005 shows that our strategies are working. In keeping with these operating objectives and our commitment to attaining profitability, we have assessed our overall operating cost structure and internal resources and have taken prudent steps to reduce variable operating expenses as a percentage of revenue. These initiatives have substantially improved our operating model, setting the stage for profitable growth.

“While the decision to reduce staff is always difficult, we believe our support level workforce reduction allows us to streamline our resources for more efficient headquarters operations without impacting our sales model or the recent sales momentum we have generated. Continuing vigilance with respect to our selling, general, administrative and pharmacy operation expenses is paramount to our operating plan as we move forward along the Company’s path to positive EBITDA and net profitability.”

For the three months ended April 1, 2006, Familymeds reported a 7% decrease in selling, general and administrative (SG&A) expenses to $13.0 million, from $13.9 million for the same period in 2005. Familymeds expects to report financial results for the second quarter ended July 1, 2006 in mid-August.
 
 
 

 
About Familymeds Group, Inc.

Familymeds Group, Inc. is a pharmacy and medical specialty product provider formed by the merger on November 12, 2004 of DrugMax, Inc. and Familymeds Group, Inc. Familymeds works closely with doctors, patients, managed care providers, medical centers and employers to improve patient outcomes while delivering low cost and effective healthcare solutions. The Company is focused on building an integrated specialty drug platform through its pharmacy and specialty pharmaceutical operations. Familymeds operates 85 locations, including 7 franchised locations, in 14 states under the Familymeds Pharmacy and Arrow Pharmacy & Nutrition Center brand names. The Company also operates Worksite PharmacySM, which provides solutions for major employer groups, as well as specialty pharmaceutical distribution directly to physicians and other healthcare providers. The Familymeds platform is designed to provide services for the treatment of acute and complex health diseases including chronic medical conditions such as cancer, diabetes and pain management. The Company often serves defined population groups on an exclusive, closed panel basis to maintain costs and improve patient outcomes. Familymeds offers a comprehensive selection of brand name and generic pharmaceuticals, non-prescription healthcare-related products, and diagnostic supplies to its patients, physicians, clinics, long- term care and assisted living centers. More information can be found at http://www.familymedsgroup.com. The Company's online product offering can be found at http://www.familymeds.com.

Safe Harbor Provisions

Certain oral statements made by management from time to time and certain statements contained in press releases and periodic reports issued by Familymeds Group, Inc., including those contained herein, that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are statements regarding the intent, belief or current expectations, estimates or projections of Familymeds, its directors or its officers about Familymeds and the industry in which it operates, and include statements in this press release related to the impact of the Company’s recent workforce and overhead reductions. Although Familymeds believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. When used in this report, the words "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are generally intended to identify forward-looking statements. Important factors that could cause the actual results to differ materially from those in the forward-looking statements include, among other items, management's ability to successfully implement its business and growth strategies, including its ability to control cost and its ability to continue its growth strategies with a smaller workforce. Further information relating to factors that could cause actual results to differ from those anticipated is included under the heading Risk Factors in the Company's Form 10-K for the year ended December 31, 2005, and its Form 10-Q for the quarter ended April 1, 2006, filed with the U.S. Securities and Exchange Commission. Familymeds disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, contact:

Cindy Berenson
Familymeds Group, Inc.
860.676.1222 x138
berenson@familymeds.com
Or
Brandi Piacente
The Piacente Group
212-481-2050
brandi@thepiacentegroup.com

 
 

 
GRAPHIC 3 familymed.jpg GRAPHIC begin 644 familymed.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_X0S[17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(```` M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-CHP-SHR M-"`Q,#HP,SHR-@```````Z`!``,````!``$``*`"``0````!````YJ`#``0` M```!````1@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```O%```` M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,0"@`P$B``(1`0,1`?_=``0` M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]523$P">8[!><4_7[K;LYF4_8<-[Q^IA M@T8YP;M;=_.^OM_L>I_@DR>2,*OJV.7Y3+S`F<=>BKXC7S?+$/I"2ROK#]8\ M#ZOXK+\L/L=<[9334`7N(&YWTW,:UC/SWHO0^MX77,!N=A[@PN+'L>(>Q[?I M5O`+F]]WTD^]::O''BX;'%O3H)*KG]4Z=TUC+.H9-6)78[8Q]S@QI=&[;O?# M53/UM^JPYZOA#S]>N/OWH\)/0KG624*K:[JF6U.#Z[&A['M,@M<-S7-/\I30 M4I))))2DD$9F(W>L[%^LW3\OKM_0J:[ MSEXK'67N=665M`+6M]]NQS_5]3]#Z;'LL1H]O%3KI))(*4DDDDI222I=4ZQT M[I-(NS[A2QQ(8(+G.(_-8Q@<]R1(&IT3&,I$1B#*1V$=2W4DDDD/_]#O?K1U M+J?2NG?;\!E5C:G@9#;0XPQWL]1GIOK^A9LW_P#!KA,7JK']2^W#I^#1=7OR MK0ZMMN+6S'MH?L#V5VTY.1F,L9E5;[-S;?\%_@K:EK?43K72G']B]( MPLEM;`_(ORKM;5ZGO?^@Q,>_TUWWU$Z)^R.AMOR&[,K-B^\NT+6Q^ M@J=^[Z57O?\`\+9:I9PX,\Q=1HBR1$`^32_P`:74?L_P!7&X%; MFMNZEQ_ MI45,])V1<]N]M>^QU-=?^$]:[U/\&]8N9U3IO7?\9/3Z&Y=+\+I%3K&'U&EM MF2^/92[=MML:]^+[6_GX]BT/\8F79%UD_1: M[]'['?SG^$_,4U:0AK9]7U+,Z/5?KKT+I-607&R\8A=4\X]3WU"YH$8)RFM^ MRUY6O\RZW]'_`(1%S/K=TS"R<7$NKO.3E64TFIE9?Z-MXW4T9=K3]GJOV?I/ M0]5]WH_IMGH^]<9U+(P&]1^K_0:F/IZ)@C[97BBMQR,MU)GO_`)[]:S+_`-%Z-BUNK4O^LGUTQ.E`.JPNE4?:NIM!`/J9#=C,2QU1U_\`1KW'WXMOTL MG=<]M=/I,V9'_:;UD7IGUKZ1U*K.M:Y^*WIC_3R_M;?1V:3N=ZGT6_U_TG^D M8N0PLRBW(ZY]>LL!W3,#]7Z/3Q6\X_Z''M8/W'9#_P!7_P`&R_)NL_G*:O3+ M]7NI4=%^HF;U:UIR,BP_;;LI[?T5N9>[]#54ZS:ZW[);]F]>YC?L_K^IZ%UC MZKO21QBM+NP/\(J=[H69]5NI]8ZGUGI]#V9V.&X^9F7,LJ!:&[MK&7[=OIMI M;ZOZ&JW^;6!]7/K!@=.P^I_7#JQL+^MY;OLE3&^I:<;'_15[&?FUT>[UK'[* MO95_A+*E2/4&](_Q:WU5;SD]3>*GY]WL9?D9DOS'UV7'>^O'QFNI^UN9Z-OI M_HGO6_9B=/;]1LX8U`]'"Z;=B8N81!NK%0LMR*/SOL^1DLW-?_VI]/UV?H/0 ML1H"QK1(C_@Q4[[_`*P]-;E]/Q6N=8[JE5F1BO8TEIKK8VYSW_G,WUV?H_:J M;?KKT)^/;DU/NMIH=M>^NFQP`AKO6=M9^CI=NV,?=Z?J;+/365]2Z67UX_6[ MW!N-T[IM'3L>QSO87,:V[JN3+PUNQF0UF'ZF_P#[1Y"K_5S-PQ]5>OAUS&DV MY+X<0#MMK;70Z#_IG_HZO](_V*MF/#(1!Z&[\&WRV&&2$YRC*7#+'$<)X?YR M7"?T9/0W_6_H5-5=YN>_&M('VEE5CJFDC=LMN#/399^_3_/5_P"$8M#-ZEB8 M5=;[G%SKCMHKK:;'V.C=MJJK#GO]JX>_*Q3_`(KV4"UAN,5>E(W^HVX6NKV? M2]1M?Z7_`(O](K'6,G&KS.A]6R'OMZ,,8T/OQWO'IV.`:Y_JXSF6,_-8_P!W M^"MK_P"#4?NFNFT9?W>)L'D8&5`3%9,V+O++[,>*'!I#U9'K,/K.!EMR"UYI M?A_TNJ\&I]4CU&NM;9&VMU?O9;_-+EOKOUG#ZAT)C<9MQK??6ZK(=4]E3PW< M7>E=8UK?H_1_TO\`@MZ;JN/TK/Z%U5WU<9;D66-I^U94VV>HUC][J*[LIS[+ M;*:O?:RK_!_HO^#5?ZQ]=Z7U'ZGXM>):SUF/I%F,WZ598(>Q[?S6_P"C_P!+ M_@D)S)B02/EO3]+R7\MRT8YL>2,9_P`[&!C+TRP^B,^+)'U?-^A_4>SSNKXF M#;70\679-H+J\>AALL+6_3LVL^@QL_2>C86;C9^+7EXK_4IM$L=!'!VN#FNA MS7-G9NT4Y%+C9OIU_T5M?O_`.-]]-RZ M#ZN965F=$Q,K+J%.1&8EZ:D>(_+^[_AO_]'U55UWYK<9M=;F?O^I^^MP@$$$2 M#H04Z2)))L]4(ABXH:UHIK#6$%HVB`1]';I^:IN8Q\;VAT$.$B8(X2D.+B8V'B MU8F-6*L>A@KKK'`:T;6MU18"=)!2T#E(M!!!`(/(^*=))2P````@#@!1]*HZ MEC>=W`^E^]_64TDE6Q?76^-[0[:9;(F"/S@I)))*?__2]527RJDDI^JDE\JI M)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J MI)?*J22GZJ27RJDDI__9_^T1ME!H;W1O.$))30/S```````)```````````!`#A"24T$"@`````` M`0``.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8``0!L M9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@`````` M`0`U`````0`M````!@```````3A"24T#^```````<```________________ M_____________P/H`````/____________________________\#Z`````#_ M____________________________`^@`````________________________ M_____P/H```X0DE-!`````````(``3A"24T$`@``````!``````X0DE-!`@` M`````!`````!```"0````D``````.$))300>```````$`````#A"24T$&@`` M```#20````8``````````````$8```#F````"@!5`&X`=`!I`'0`;`!E`&0` M+0`Q`````0`````````````````````````!``````````````#F````1@`` M```````````````````!`````````````````````````!`````!```````` M;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4 M;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````1@`` M``!29VAT;&]N9P```.8````&7!E`````$YO;F4````)=&]P3W5T M/S1B>4I(6TE<34Y/2EM<75Y?56 M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$# M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:F MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]523$P">8[!><4_7[K;L MYF4_8<-[Q^IA@T8YP;M;=_.^OM_L>I_@DR>2,*OJV.7Y3+S`F<=>BKXC7S?+ M$/I"2ROK#]8\#ZOXK+\L/L=<[9334`7N(&YWTW,:UC/SWHO0^MX77,!N=A[@ MPN+'L>(>Q[?I5O`+F]]WTD^]::O''BX;'%O3H)*KG]4Z=TUC+.H9-6)78[8Q M]S@QI=&[;O?#53/UM^JPYZOA#S]>N/OWH\)/0KG624*K:[JF6U.#Z[&A['M, M@M<-S7-/\I304I))))2DD$9F(W>L[%^ MLW3\OKM_0J:[SEXK'67N=665M`+6M]]NQS_5]3]#Z;'LL1H]O%3KI))(*4DD MDDI222I=4ZQT[I-(NS[A2QQ(8(+G.(_-8Q@<]R1(&IT3&,I$1B#*1V$=2W4D MDDD/_]#O?K1U+J?2NG?;\!E5C:G@9#;0XPQWL]1GIOK^A9LW_P#!KA,7JK'] M2^W#I^#1=7ORK0ZMMN+6S'MH?L#V5VTY.1F,L9E5;[-S;?\%_@K:EK M?43K72G']B](PLEM;`_(ORKM;5ZGO?^@Q,>_TUWWU$Z)^R.AMOR&[ M,K-B^\NT+6Q^@J=^[Z57O?\`\+9:I9PX,\Q=1HBR1$`^32_P`: M74?L_P!7&X%;FMNZEQ_I45,])V1<]N]M>^QU-=?^$]:[U/\&]8N9U3IO7?\9/3Z&Y=+ M\+I%3K&'U&EMF2^/92[=MML:]^+[6_GX]BT/\8F79%UD_1:[]'['?SG^$_,4U:0AK9]7U+,Z/5?KKT+I-607&R\8A=4\X]3 MWU"YH$8)RFM^RUY6O\RZW]'_`(1%S/K=TS"R<7$NKO.3E64TFIE9?Z-MXW4T M9=K3]GJOV?I/0]5]WH_IMGH^]<9U+(P&]1^K_0:F/IZ)@C[97BBMQR,MU)GO_`)[]:S+_`-%Z-BUNK4O^LGUTQ.E`.JPNE4?:NIM!`/J9 M#=C,2QU1U_\`1KW'WXMOTLG=<]M=/I,V9'_:;UD7IGUKZ1U*K.M:Y^*WIC_3R_M;?1V:3N M=ZGT6_U_TG^D8N0PLRBW(ZY]>LL!W3,#]7Z/3Q6\X_Z''M8/W'9#_P!7_P`& MR_)NL_G*:O3+]7NI4=%^HF;U:UIR,BP_;;LI[?T5N9>[]#54ZS:ZW[);]F]> MYC?L_K^IZ%UCZKO21QBM+NP/\(J=[H69]5NI]8ZGUGI]#V9V.&X^9F7,LJ!: M&[MK&7[=OIMI;ZOZ&JW^;6!]7/K!@=.P^I_7#JQL+^MY;OLE3&^I:<;'_15[ M&?FUT>[UK'[*O95_A+*E2/4&](_Q:WU5;SD]3>*GY]WL9?D9DOS'UV7'>^O' MQFNI^UN9Z-OI_HGO6_9B=/;]1LX8U`]'"Z;=B8N81!NK%0LMR*/SOL^1DLW- M?_VI]/UV?H/0L1H"QK1(C_@Q4[[_`*P]-;E]/Q6N=8[JE5F1BO8TEIKK8VYS MW_G,WUV?H_:J;?KKT)^/;DU/NMIH=M>^NFQP`AKO6=M9^CI=NV,?=Z?J;+/3 M65]2Z67UX_6[W!N-T[IM'3L>QSO87,:V[JN3+PUNQF0UF'ZF_P#[1Y"K_5S- MPQ]5>OAUS&DVY+X<0#MMK;70Z#_IG_HZO](_V*MF/#(1!Z&[\&WRV&&2$YRC M*7#+'$<)X?YR7"?T9/0W_6_H5-5=YN>_&M('VEE5CJFDC=LMN#/399^_3_/5 M_P"$8M#-ZEB85=;[G%SKCMHKK:;'V.C=MJJK#GO]JX>_*Q3_`(KV4"UAN,5> ME(W^HVX6NKV?2]1M?Z7_`(O](K'6,G&KS.A]6R'OMZ,,8T/OQWO'IV.`:Y_J MXSF6,_-8_P!W^"MK_P"#4?NFNFT9?W>)L'D8&5`3%9,V+O++[,>*'!I#U9'K M,/K.!EMR"UYI?A_TNJ\&I]4CU&NM;9&VMU?O9;_-+EOKOUG#ZAT)C<9MQK?? M6ZK(=4]E3PW<7>E=8UK?H_1_TO\`@MZ;JN/TK/Z%U5WU<9;D66-I^U94VV>H MUC][J*[LIS[+;*:O?:RK_!_HO^#5?ZQ]=Z7U'ZGXM>):SUF/I%F,WZ598(>Q M[?S6_P"C_P!+_@D)S)B02/EO3]+R7\MRT8YL>2,9_P`[&!C+TRP^B,^+)'U? M-^A_4>SSNKXF#;70\679-H+J\>AALL+6_3LVL^@QL_2>C86;C9^+7EXK_4IM M$L=!'!VN#FNAS7-G9NT4Y%+C9OIU_T5 MM?O_`.-]]-RZ#ZN965F=$Q,K+J%.1&8EZ:D>(_+^[_AO_]'U55UWYK<9M=;F? MO^I^^MP@$$$2#H04Z2)))L]4(ABXH:UHIK#6$%HVB`1]';I^:IN8Q\;VAT$. M$B8(X2D.+B8V'BU8F-6*L>A@KKK'`:T;6MU18"=)!2T#E(M!!!`(/(^*=))2P` M```@#@!1]*HZEC>=W`^E^]_64TDE6Q?76^-[0[:9;(F"/S@I)))*?__2]527 MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDD MI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9`#A"24T$(0``````4P````$!```` M#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`FMC.60G M/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T M:STG6$U0('1O;VQK:70@,RXP+3(X+"!F&UL;G,Z6YT87@M;G,C)R!X;6QN&UL;G,Z M97AI9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\G/@H@(#QE>&EF M.D-O;&]R4W!A8V4^,3PO97AI9CI#;VQO&EF.E!I>&5L M6$1I;65N&EF M.E!I>&5L641I;65N&UL;G,Z<&1F/2=H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O)SX* M(#PO&%P.DUE=&%D871A1&%T93XR,#`V+3`W+3(T5#$P.C`S.C(V+3`U.C`P M/"]X87`Z365T861A=&%$871E/@H@(#QX87`Z0W)E871O&%P34TZ1&]C M=6UE;G1)1#X*(#PO#IX;7!M M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!`0`` M#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C%```8VEA96B`````````D MH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W M`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(! M.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J(" MK`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B M`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$ MTP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G M!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&09!ZP' MOP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY M"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+ M@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI M#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0 M)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$)%ZX7TA?W&!L80!AE&(H8KQC5 M&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H< M4AQ['*,0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J M(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B--@U$S5--8Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$25^!8+UA]6,M9&EEI6;A:!UI66J9: M]5M%6Y5;Y5PU7(9O5\/7V%?LV`%8%=@JF#\84]AHF'U M8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-I MFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z M<95Q\')+%V/G:;=OAW5G>S>!%X;GC,>2IY MB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'- M@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2* MRHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.V ME""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>= M9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;] MIVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;& MP\=!Q[_(/%$XIZ#+HO.E& MZ=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#U MWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N`"%!9&]B M90!D0`````$#`!`#`@,&````````````````_]L`A``$`P,#`P,$`P,$!@0# M!`8'!00$!0<(!@8'!@8("@@)"0D)"`H*#`P,#`P*#`P,#`P,#`P,#`P,#`P, M#`P,#`P,`00%!0@'"`\*"@\4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P@`1"`!&`.8#`1$``A$!`Q$! M_\0`UP`!``("`P$!``````````````<(!08"`P0!"0$!``(#`0$!```````` M``````(%`0,$!@<($```!P`!`P,$`@,!```````!`@,$!08'`!$2"!`Q$S!` M(10@8%`5%A<1``("`0,#`00'`P@+``````$"`P0%$1(&`"$3(C%!%`=183)" M4B,5<8(S$"`P0&*#)!90@9%R0U-SDR87"!(``0,"`P,'"@4%`0```````0`1 M`A(#(3$B$$%A(%$R0E(3!$#P@9&AL=%B(8[8V1K)@``")*_UTMV'D0,5 MKZZ@T'UWENY-VN?CD6<_CKD]7KXUL=W;ANFG/W#V8SP8[L.K+Q9?&._-;.(4?\U]MQUYY7P7/R&,J M#Q/Z=]WTVH-ZDCFSBYH\Z,3'PRC/LCC\MGU-/W8D3EEO^G-:[*$J>9]AFJ^W MU?19]N8^C.O;NBJU/1:>:.S8]U=G-O%,]CXL1[R>AI7<2[[;RU@?+4D[=/H: MD7.NYE)LI_0,!004$B+`G4_[0@9P3O5F#`J M#9`AD8],IP;!V..XRBY$%/E:C\RKDH%J9Q(9PM\I_ID+W&,V M*B=545#?T7__V@`(`0,``04`^^;ME5SNXYRU^\I0)_#8`3%A(.Q;)1\NJHKP M1YW<[OY@/7@"/7Z#"O`X:>K,J1EFM72;'GVCM8D?VFEK>-'J]6;'FSBXAOB09Q+B69C'SQ!C6$(NHK#U)5`2S3-VQ M;^D!(_I.[4BDF_*'7D4P,B;@=>O``>O0>I@Z\,'#!^`Z\`!X(#U#A?SROKMV M[F469NG]DD&NL*U>*C<2_=^7*DK_O<.4ED]6W' M2G&5T#$O)Z^S]_Y?;NC0(2L^3%7N:-=WRO6*\_QMEIA:57<^T"OZ;6*+MVGW M/;OH7#;1K5]];*XFVD!8O(Z8MD=G6HJUX;'KV=WG-LQG/&O-[)1;Q#:'7O+" MWA5L<\6JD6G8S64:E=9:RZYG%32;Z+3%J;"Z;0+#7JSHE(N434M-H-[=ZA/9 M?'UQ=U3\IS#Q*:,Z_2J]:Z;8Z_:-TDY:+A&<#;JM:`]/(BA_\=>D)Q]DA6_(A.1LU\WF&S302:QC3I/6-3UJ(C(KR#\EHZS).\GM>?Z':/ M3:*&%_HFIT&:E#T.MX M_K,/M^ZY;?=`>^2%#NMLJ6X9];&F)8AG][IM>R#(MP-;=0S[5Y7?Z+79>LPW MC15'6B3VUPUJM%-SV*OU3RS!*3H.9I5.D:?":]?\IT&OZ'37&QV*1+F.F9-H M5XJ&Q7'191;4H>V9CFDTQTKULM8B;56L*U2B/2JW!'#E"(S M*IDJW+G+\$0;D$QS32B#ZU3:@']*:\!CV4Z=#ABBV[!=V>=T&&:H;%")&)3$ M8E/(,G@,0@)9DJ-N.Y4D8II8)W#*IPRTETY++273R+*!B7R]ZDWO49`.`JAA)L1M(W[E1+=T?T3#.2+IB67=QD/;L`&+=7XH1)?@/] M>`4I'`[@C.9Q1G,HT[STO@@!J;=U?N1B2Q+NM(8#)?,13\53$.ZI,<1Q1!&? M%&X8Y\0N\MIYM$#VJJ`<%1E3EQ0DS@C&+HW"*0=W(!&Y5?B`9.JI'2/\I<$9 M'\C?_]H`"`$#`@8_`/+J+<3*1W!#OH&#\_Q\LN$=.H/]#:?W5*[7DV'U]3VH MS`F65/MY$8W21`G48YCCZ%7:NW(G@8_QQ M0GXN_=D'TP%&J7"(B!]Q0C`7*#F9T]+4CNP5<$80F1&)CI'1+B+U#K/Q5 ML6I&%0-5.$C2=.K-AS*U=GC/27XD$2]:MU2G#OFE.=L`SDXJH+F.EO=Q1\)# MO+A=X2N".DO]1\RK5BSIK/\`Z2&[F0L^*D;])K,@].)JC2\8=GZB,5*R;E$XS MJMW91.J)`>,J:B,1YXJWX6$S=E%C.XQ`TNP%6HYY\.1C^5?_V@`(`0$!!C\` M_KTF4SMZ''8Z+0/9LN(TU/L`)]I/N`[]2MQC,5LF8/XT<#ZR(#V!9#HP'UZ: M?USC<,A?]"^%F>`=_$;GDTD^K<$V:?43]?7&OT??YGL%+8370TRC&??_`&0O M?O\`>V]6N34*R6LI)-%1Q\?<0\@!!*JJL=`?4=%ZQG%N:/7R6-SDOP ML,T,"5YJT[`F,CQZ!D)&U@PW?>W=M#T_(;N'R65QE?%113O6AC4NTLBR M2Q'8`.Y7=I[^W4]CBG%.4YB&JRQVI*>-CE6-W&X*Q%C34COIU6^7B\=Y#B^2 M68Y+'BRU%*:1P1(7:1]TQ;;VV@JK:MV_G9#E/(9S7P^,B\UF55+MIJ%554=R MS,0JCZ3U#RSB[3-C9Y)80EJ/PRI+`Q1E==6T[_03U<^6EK%8C'XG`O;;.SU& MGN/XJWY:A)G:-=6D=!_"_%V_H<7P"'`6&N9"U5A.0MNL-*61!N\9V$'5@-!W^UT^(Y+Q'"Y"@6#&O8%G M5'7WJ1(&1A[-5(/62O\`&^*\VO5]/F1=K9?C%^TE*&YQBM<\E*W&GEC,XM[7BE.A:+5-CJK]W]2]1\J;, M9S-Y2IN_31:QXBBKLZE2^U#ZGT)`).@_#K[(N3\?2RN)GDDBKR6X37:3Q':S M*I)U7=JNOTJ>LI5BDV7N0R1X>OH=&V3ZO.?^TCC][K$3VT\%S-^3-W&D].B6 M=/#J3[A"D9ZI?-O#&:>>2A8PV/LRCQQ/3%LL\D:$:Z2/%JCZ^J/30>KK*-F. M245MX>$V+V-@GCFO*H8+H*Z,7+%B!MTUZI\_GRL5#BEZ%+$%_($TU*2:[05F MVG<=.RZ:M]W7J[RS$*"!XPK$.TNW3LR^WVZ]NK>=XSG:F M0Q&/=H[UQ)-D<#(H<^0R;=HVG=N/IT[]7:/#^04\Q;QX#6XJK[BJ,2H<:@;E MU&FY=5^OJQA_FGD*%?`95?%+2O2[&G4,&]"(?(=I`.Y/LGW]6\KQVM7I\4P> M.EOT8*Y)BD4H94T8DEC*S#U$DL6ZY9\Y>:W(J/Z]=D,V2N,(T6O7=FD?>W_, MGD<:?>*+U_F?CN5KY#`?F%KT+?EKX=?('UT*E=.X8#I>587-5+?'&+C]3655 M@!C.C!F?3:0?;NZK9R?D-&'$W2ZT[4TZQ)-XG,;F/>06`92-1VZ7D+9BDN"8 M:KDC8C%8_LDW;=?JUZ>UQ[*5WN/9*ME*4.9FGE##H9EJ3I,R`^PLJDD`_7_++DJE>R[MS: M5OEN8?!G9+IHW55EF6OXCK.[-&64^)0Q;0_=V]8_CV(B\.,QE>.K5C]XCB4* M"?I)TU8^\]<)^4>-D)$30BR!]RQE)%!8_P#3@CW_`+&ZR>.X7?S:Y[X818N" MSFK34RPT4))'(S)X]OM7;^SKC?\`\O\`RKN-C?AJD%?E.?K=IJ>.K0J7BA8? M9D,8!9O;N=$'=FTX)_\`/WRZQ52MSLS[*]16],<:^7[<@*YSF'-QX?EW3N6<[EJA`2 M'*WZJ[@)$[!JM8+JL7V)K#^KTPA3SCYP7:ZU%SEN2ECZ\:A(U5Y?BIPJC0!5 M)BC&GX&ZP7RPQ3SY*\)/CN99^V_FMO'+I.\&X:+'%!754BBC5$5Y?87]76!^ M6^#0+=Y+[7,A&]%=H][$JA[?1U2PV5JJF7?8C*2RJGB=M3&%V@ M@)H->_OZST_(\?%E13GACJ5[B^>O#YXBTC)$^J!WT&Y]N[11WZY9QW#@U\.D M=V)*H)*B..6)XU[GOLW$+K[NN0-1I8W*GB:2U<3C6/7[77*.4\N1I,\;<^+QL\H),E5)-TMH$]_ M\0VW0^W:I_%T;N-PES/V]ZQIC\>U=)3NU]1:S+"@4:=SNU_L]6OG%S+Y?W;D M$\EN:&E3MX^6:N9HO!`%$MA`WBB]'M7\722%&C9U#&-]-RDC70[21J/J/7+\ M[D:5;#V\\T]>QRNY+%:DB2:SYI):=="WD=P%V>79&FB[@^GC.?Y'Q_"UL?C( MTFQ^&Y/F;`MF**4*KWQ$CF2S9E'D9O)L3R2MO.T;>OEW\O*`MY#AE.7XCDW) MK,T)E,BZ1EY5U0E_'Y"NQ-NZ0#MMZXK\M?EUB=./S7(8\I8C>..&E4IJJ0!E M9U8H"V_TAOX0'OZQ?RO^4^)>]4$E6A>CCDBBE^!A!D9CY&0$RRJID.OWF^GK M'1\HE@H0XG'FEB^)XV4O7\TC>6:U=G/:6Q*X[;?RH%9MFXL3URCE/)8HN*6^ M42N,GGFECL9:.O),TLT-".-GCC,AV*)Y/X:(OC0GK!ZM M<4XMBA>FRFP3VY+$5>.NL,T_J3BM[C8ES>.CE@HI'=K>*T M+,/ZMWVON:]9C'9[`I)6R&VS#:KW*[;9:\3*(F4L#^8=`K>Q?O= M9/YCW.,QMC\N]A7IQY"L9H8[+)HVI8*Q4)Z@/W>I/F=\JC'8LW&,M['.Z(PD MZ-WCD7=V^TOVAUQKEQXQ6K2 M8N*M.M5;J/%$*]II?'-.P4&1OHB1@J[?:>J7*JN"&6PM_&I2SF`J7D9ZUF&: M1TE@-CPHY*OM?LN[]U3UGOF1DL5'QK'7XY(<9@4DCEE7S&,O))X2T:ZF/=M4 M_:?ZN_\`+DN*92%3B)PRK:O*SV12H ML6YCZWT/<``*BC\*C^DRN=AI2Y*;&U)[<>/K=YIV@C+B-.Q[MIH.W5CC7".- M7<5S7*))0R-^Q&QQ&*KRZH]DVF5/(_C)\4*KY/)[=%7=UC^(<>C*TJ2:RSN! 6Y;$[]Y)I"/:SG_8-%'I4?USM_HK_V3\_ ` end
-----END PRIVACY-ENHANCED MESSAGE-----